IOP

Beijing, China
Beijing, China

Time filter

Source Type

News Article | May 23, 2017
Site: www.marketwired.com

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Convalo Health International, Corp. ("Convalo" or the "Company") (TSX VENTURE:CXV), a leading company in the United States addiction recovery industry, today announced it has executed a management services agreement ("MSA") with an operating partner to operate the Company's 18-bed detox and residential center located in the heart of Hollywood, California. Since executing the MSA earlier in May, the operating partner has increased census by over 90%. The financial impact of these results will only begin to be reflected in May 2017, the third month of the first fiscal quarter. No additional corporate overhead has been incurred by Convalo as a result of executing the MSA. This MSA is another example of Convalo implementing its new strategy. The operating partner has been in the addiction treatment industry for many years and specializes in marketing specifically to residential and detox patients. Previously, the partner's business model centered only on helping detox centers source potential patients, rather than benefiting from operating their own center. With the new partnership, the operating partner has now turned its resources to filling the 18 bed center and has expressed interest in operating further residential and detox centers once the relationship has developed with Convalo. "This experience with our new operating partner is an example of the leverage we can achieve with our new strategy," said Chris Heath, CEO of Convalo. "Since taking over the residential center, they have increased patient enrollment quickly and significantly, bringing census from about one third to about two thirds full in a matter of weeks. I believe with their background and expertise, we could see a near capacity center there soon. We have moved all payroll and associated operating costs from Convalo's responsibility to that of the operating partner, reducing operating costs for the month of May. These costs savings will be most visible in our second quarter ending in August, when those savings could be achieved in each month of the quarter. My team and I continue to look for new operating partners since changing our model earlier in the year. All things being equal, we have the cash on the balance sheet to double our revenues." Convalo has shifted to a strategy of decentralizing treatment operations, including sales and marketing functions. The majority of the current location's management and staffing decisions, including sales and marketing, now reside with a local leadership team at each individual center through an MSA. Convalo is shifting the clinical and operational staff management and hiring at each individual center, as well as the majority of the sales and marketing responsibilities of the clinics, to the local general managers and outreach leaders through an MSA, enabling these leaders to make cost decisions independently. The model allows local operators to keep some of the annual cash flow generated from their operations and aligns incentives between the Company and the operators. These leaders, the majority of whom have already executed an MSA, have been established at the current seven sites, in some cases for as long as two years. Because of the previous "centralized" management model, they were restricted from hiring local staff and managing the center as a "stand alone" or decentralized model. Further, they were not incentivized to use local marketing techniques, which are often a fraction of the cost of national advertising. The previous management team attempted to centralize all aspects of the centers, from staffing and back office to sales and marketing, resulting in expenditure of a tremendous amount of time, energy and money without commensurate rewards in revenue growth. "With the new model," explained Mr. Heath, "we should be able to expand more rapidly and limit our risk if one of our partners underperforms." Under the new model, Convalo will continue to own or lease its existing facilities (depending on the market) and provide branding support, facilities (real estate, furniture, fixtures and equipment) management and upkeep, call center services, clinical protocols, and documentation support to all centers. Convalo will continue to maintain control of these facilities in the event a change in local management is someday needed. For new facilities, Convalo will have the flexibility to decide whether to own or lease, and management will focus upon speed to profitability and return on equity in deciding upon the proper structure. Convalo will shift corporate ownership costs at new locations to the local operational and outreach leaders, incentivizing them like partners instead of employees. As part of incentives for the new team, the Board issued 100,000 options to Mr. Jason Monroe as COO. In addition, the Board issued 1,400,000 options to parties at Convalo that are key to the success of the new business model. All options have a strike price of $0.165, vest 1/3 each in May 2018, 2019 and 2020 respectively, and have a 10-year exercise provision. Convalo, operating under the brand name BLVD Centers (www.blvdcenters.com), is a leader in the highly fragmented addiction rehabilitation market. Led by a new executive management team, Convalo is well positioned for continued national expansion by launching pods in cities across the United States. A pod consists of a residential, detox, and mental health facility (detox facility) and an intensive outpatient (IOP) facility. Convalo, under the BLVD brand, is focused upon becoming the largest national provider of a range of mental health services, including addictive and co-occurring disorders. In conjunction with the long standing 12-Step approach, BLVD also offers supplemental insurance-reimbursed services catering to a variety of communities: gender specific, creatively-oriented, meditation/mindfulness, trauma and LGBT affirmative. Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, near capacity patient enrollment soon at the Hollywood detox and residential center, costs savings in the second quarter, expanding more rapidly and limiting risk under the new model, and the Company shifting corporate ownership costs to the local operational and outreach leaders, incentivizing them like partners instead of employees, are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Material factors or assumptions were applied in providing forward-looking information, including: insurance reimbursement remains at levels similar to today, census levels and patient demand remains strong, partners operate their locations profitably, partners reimburse the Company for any and all working capital loans, additional corporate overhead is not needed). Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation, changes in law, the ability to implement business strategies and pursue business opportunities, state of the capital markets, the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, difficulty integrating newly acquired businesses, the outcome and cost of any litigation with insurance providers, low profit market segments, as well as general economic, market and business conditions, as well as those risk factors discussed or referred to in Convalo's annual Management's Discussion and Analysis for the year ended February 29, 2016, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect Convalo in an unexpected manner, or should assumptions underlying the forward looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Convalo does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward -looking information included in this press release is made as of the date of this press release and Convalo undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. Convalo's results and forward-looking information and calculations may be affected by fluctuations in exchange rates. All figures are in Canadian dollars unless otherwise indicated.


IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful primary efficacy results of the Company’s 90-day Phase 3 “Mercury 2” registration trial for its fixed-dose combination product candidate, Roclatan™. The results of Mercury 2 were consistent with the successful 90-day efficacy results from the Mercury 1 trial, a 12-month Phase 3 registration trial for Roclatan™, which reported topline efficacy findings in September 2016. Mercury 2 achieved its primary efficacy endpoint of demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa™ (netarsudil ophthalmic solution) 0.02%, and market-leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening. The IOP-lowering effect of Roclatan™ was 1 to 3 mmHg (millimeters of mercury) greater than monotherapy with either latanoprost or Rhopressa™ throughout the duration of the study. The study evaluated patients with maximum baseline intraocular pressures (IOPs) ranging from above 20 to below 36 mmHg. Management will host a conference call with accompanying slides to discuss these results at 5:00 p.m. Eastern Time (ET) today. The accompanying slides are available at Aerie’s website, aeriepharma.com. “With this positive Mercury 2 data, we now have two successful pivotal trials for Roclatan™. The topline efficacy results demonstrated in Mercury 2 are consistent with Mercury 1, confirming the potential for Roclatan™ to become the most efficacious IOP-lowering therapy to enter the market, if approved. Now that the efficacy results for both Mercury 1 and 2 have proven successful, and if the Mercury 1 12-month safety results are also successful, we expect to submit our Roclatan™ NDA (new drug application) in the first half of 2018,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie. Dr. Anido continued, “In addition to the excellent efficacy observed in Mercury 2 for both Roclatan™ and Rhopressa™, we were also delighted to see relatively low discontinuation rates for the 90-day Mercury 2 trial of 9.8 percent and 10.6 percent for Roclatan™ and Rhopressa™, respectively.” Richard A. Lewis, M.D., Aerie’s Chief Medical Officer, added, “Roclatan™ is distinguished by its ability to lower intraocular pressure to levels previously unseen with current glaucoma therapies, including market-leading latanoprost. This product holds the promise of potentially becoming the first prostaglandin fixed-dose combination available in the United States. The safety profile of Roclatan™ observed in Mercury 2 once again points to a safe and tolerable product.” Roclatan™ is a once-daily eye drop that combines Rhopressa™, as described below, with latanoprost, a widely prescribed PGA. Based on the Company’s preclinical studies and clinical trials to date, Aerie believes that Roclatan™, if approved, would be the first glaucoma product to lower IOP through all known mechanisms: (i) increasing fluid outflow through the trabecular meshwork, the eye’s primary drain, (ii) increasing fluid outflow through the uveoscleral pathway, the eye’s secondary drain, (iii) reducing fluid production in the eye, and (iv) reducing episcleral venous pressure (EVP). By covering the full spectrum of known IOP-lowering mechanisms, Roclatan™ has the potential to provide a greater IOP-lowering effect than any currently approved glaucoma product. The first Phase 3 registration trial for Roclatan™, named Mercury 1, is a 12-month safety trial, which had a successful 90-day efficacy readout in September 2016. The 12-month safety data from this trial are expected in the third quarter of 2017. The second Phase 3 registration trial, named Mercury 2, is a 90-day efficacy trial, which just completed and is the subject of this press release. The topline 90-day efficacy readouts for both Mercury 1 and Mercury 2 demonstrated that Roclatan™ was statistically superior to each of its components, thus achieving their primary clinical endpoints. Aerie expects to submit a Roclatan™ NDA to the U.S. Food and Drug Administration (FDA) in the first half of 2018. A third Phase 3 registration trial, named Mercury 3, is expected to commence in Europe in mid-2017. Mercury 3 is not necessary for approval in the U.S., but rather to facilitate regulatory approval and commercialization in Europe. Rhopressa™ (netarsudil ophthalmic solution) 0.02%, is a novel eye drop that the Company believes, if approved, would become the only once-daily product available that, based on Aerie’s preclinical and clinical studies to date, specifically targets the trabecular meshwork, the eye’s primary fluid drain and the diseased tissue responsible for elevated IOP in glaucoma. Preclinical and clinical studies have also demonstrated that Rhopressa™ lowers episcleral venous pressure, which contributes approximately half of IOP in healthy subjects. Further, based on Aerie’s preclinical studies, Rhopressa™ may provide an additional mechanism that reduces fluid production in the eye and therefore lowers IOP. Biochemically, the active ingredient in Rhopressa™, netarsudil, has been shown in Aerie studies to inhibit both Rho kinase (ROCK) and norepinephrine transporter (NET). Recent preclinical studies have also shown that Rhopressa™ may have disease-modifying properties, including an anti-fibrotic effect of netarsudil on trabecular meshwork cells and the potential to increase perfusion of the trabecular meshwork. The results of two Phase 3 registration trials (Rocket 2 and Rocket 1) for Rhopressa™ were included in the NDA submission to the FDA in February 2017. There were two additional Phase 3 registration trials for Rhopressa™, named Rocket 3 and Rocket 4. Rocket 3 was a small 12-month safety-only study in Canada that was not necessary for the NDA submission and for which enrollment has been discontinued. Rocket 4, which was successfully completed in April 2017, was designed to provide adequate six-month safety data for regulatory filing purposes in Europe, and was also not necessary for the NDA submission. The 90-day efficacy results from Rocket 4 and Mercury 1, the initial Phase 3 registration trial for Aerie product candidate Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, were also included in the Rhopressa™ NDA submission as supportive. The FDA has set the Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review of the Rhopressa™ NDA for February 28, 2018. Aerie management will host a live conference call and webcast at 5:00 p.m. ET today to discuss the Roclatan™ Phase 3 efficacy results from Mercury 2, including a review of the associated slides that are posted on Aerie’s website, aeriepharma.com. The live webcast and a replay may be accessed by visiting Aerie's website at http://investors.aeriepharma.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 28687184. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 28687184. The telephone replay will be available until June 1, 2017. Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two current product candidates are once-daily intraocular pressure lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA for Rhopressa™ (netarsudil ophthalmic solution) 0.02% was submitted to the FDA in February 2017, and, in May 2017, the FDA set the PDUFA goal date for the completion of the FDA’s review of the Rhopressa™ NDA for February 28, 2018. Aerie’s second product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and widely prescribed PGA latanoprost, achieved its primary efficacy endpoint in two Phase 3 registration trials, named Mercury 1, which is still ongoing, and Mercury 2. A Roclatan™ NDA submission is expected to take place in the first half of 2018. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology. This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success, timing and cost of our ongoing and anticipated preclinical studies and clinical trials for our current and potential future product candidates, including statements regarding the timing of initiation and completion of the studies and trials; our expectations regarding the clinical effectiveness of our product candidates and results of our clinical trials; the timing of and our ability to request, obtain and maintain FDA or other regulatory authority approval of, or other action with respect to, our product candidates, including the expected timing of, and timing of regulatory and/or other review of, filings for our product candidates; our expectations regarding the commercialization and manufacturing of our product candidates; the potential advantages of our product candidates; our plans to pursue development of additional product candidates and technologies in ophthalmology, including development of our product candidates for additional indications and other therapeutic opportunities; our plans to explore possible uses of our existing proprietary compounds beyond glaucoma; our ability to protect our proprietary technology and enforce our intellectual property rights; and our expectations regarding strategic operations, including our ability to in-license or acquire additional ophthalmic products or product candidates or technologies. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). In particular, the topline Mercury 2 data presented herein is preliminary and based solely on information available to us as of the date of this press release and additional information about the results may be disclosed at any time. The receipt of the PDUFA goal date notification does not constitute FDA approval of the Rhopressa™ NDA, and there can be no assurance that the FDA will complete its review by the PDUFA goal date, that the FDA will not require changes or additional data, whether as a result of recommendations, if any, made by any FDA advisory committee or otherwise, that must be made or received before it will approve the NDA, if ever, or that the FDA will approve the NDA. In addition, the preclinical research discussed in this press release is preliminary and the outcome of such preclinical studies may not be predictive of the outcome of later clinical trials. Any future clinical trial results may not demonstrate safety and efficacy sufficient to obtain regulatory approval related to the preclinical research findings discussed in this press release. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


LOS ANGELES, May 2, 2017 /PRNewswire/ -- Insight Treatment Programs, the L.A. area's first Intensive Outpatient Program (IOP), is partnering with UCLA in a study for Parents of Teens in Substance Abuse Treatment. The study, titled "Purpose," will examine the use of private F...


Published recently in US Ophthalmic Review, the peer-reviewed journal from touchOPHTHALMOLOGY, Sameh Mosaed discusses the COMPASS study - the largest randomized clinical trial to date on a minimally invasive glaucoma surgery device, the CyPass® Micro-Stent. The CyPass Micro-Stent was able to lower intraocular pressure (IOP) more than modern cataract surgery (phacoemulsification and intraocular lens implantation) alone, and should be considered for patients with mild to moderate glaucoma already scheduled to undergo phacoemulsification surgery. The two-year outcomes of the COMPASS study found mean IOP reductions of 7.4 mmHg in the CyPass Micro-Stent group and no vision-threatening adverse events; more than 98% of subjects in the CyPass Micro-Stent group achieved 20/40 or better best-corrected visual acuity. The full peer-reviewed, open-access article is available here: Disclosure: Sameh Mosaed is a speaker and consultant for Alcon Laboratories. The publication if this article was supported by Alcon Laboratories. touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the US Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Providing practical opinion to support best practice for busy healthcare professionals.


News Article | May 4, 2017
Site: www.cemag.us

A recent study, affiliated with UNIST, has proposed the possibility of in situ human health monitoring simply by wearing a contact lens with built-in wireless smart sensors. This study has been jointly conducted by Professor Jang-Ung Park of Materials Science and Engineering, Professor Chang Young Lee of Life Science, and Professor Franklin Bien of Electrical and Computer Engineering at UNIST in collaboration with Professor Hong Kyun Kim of Ophthalmology and Professor Kwi-Hyun Bae of Internal Medicine at Kyungpook National University (KNU). In the study, the research team unveiled a smart contact lens sensor that could help monitor biomarkers for intraocular pressure (IOP), diabetes mellitus, and other health conditions. The research team expects that this research breakthrough could lead to the development of biosensors capable of detecting and treating various human diseases, and used as a component of next-generation smart contact lens-related electronic devices. Diabetes is the most common cause of high blood sugar levels. Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma. If this condition persists for more than two hours, a patient will be diagnosed with diabetes. Since blood sugar can be measured with tears, many attempts have been made to monitor diabetes with contact lenses. Despite numerous studies in the last several decades, the biggest drawback with conventional smart contact lenses was thought to be poor wearability. The electrodes used in existing smart contact lenses are opaque, and therefore obscure the view when wearing it. Moreover, because they lens-shaped firm plastic material, many people complain of comfort issues with contact lens wear which made wearing them impossible. Park and his research team solved these issues by developing a sensor based on transparent and flexible materials. Their new smart contact lens sensors use electrodes made of highly stretchable and transparent graphene sheets and metal nanowires. Using this sensor, patients with diabetes and glaucoma may one day be able to self-monitor blood glucose levels and eye pressure. Through the embedded wireless antenna in the contact lens sensor, patients can also transmit their health information, which allows real-time monitoring of their health conditions, as well. In addition, because the system uses wireless antenna to read sensor information, no separate power source, like battery is required for the smart contact lens sensors.


News Article | May 4, 2017
Site: phys.org

This study has been jointly conducted by Professor Jang-Ung Park of Materials Science and Engineering, Professor Chang Young Lee of Life Science, and Professor Franklin Bien of Electrical and Computer Engineering at UNIST in collaboration with Professor Hong Kyun Kim of Ophthalmology and Professor Kwi-Hyun Bae of Internal Medicine at Kyungpook National University (KNU). In the study, the research team unveiled a smart contact lens sensor that could help monitor biomarkers for intraocular pressure (IOP), diabetes mellitus, and other health conditions. The research team expects that this research breakthrough could lead to the development of biosensors capable of detecting and treating various human diseases, and used as a component of next-generation smart contact lens-related electronic devices. Diabetes is the most common cause of high blood sugar levels. Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma. If this condition persists for more than two hours, a patient will be diagnosed with diabetes. Since blood sugar can be measured with tears, many attempts have been made to monitor diabetes with contact lenses. Despite numerous studies in the last several decades, the biggest drawback with conventional smart contact lenses was thought to be poor wearability. The electrodes used in existing smart contact lenses are opaque, and therefore obscure the view when wearing it. Moreover, because they lens-shaped firm plastic material, many people complain of comfort issues with contact lens wear which made wearing them impossible. Professor Park and his research team solved these issues by developing a sensor based on transparent and flexible materials. Their new smart contact lens sensors use electrodes made of highly stretchable and transparent graphene sheets and metal nanowires. Using this sensor, patients with diabetes and glaucoma may one day be able to self-monitor blood glucose levels and eye pressure. Through the embedded wireless antenna in the contact lens sensor, patients can also transmit their health information, which allows real-time monitoring of their health conditions, as well. In addition, because the system uses wireless antenna to read sensor information, no separate power source, like battery is required for the smart contact lens sensors. Intraocular pressure measurement can be achieved using the dielectric layers. The dielectric layer is an electrically non-conductive layer, characterized by polarity that divides both positive and negative charges. The thickness of this layer changes from thinning as the intraocular pressure increases, to thickening as the intraocular pressure decreases. The IOP sensor, embedded in the contact lenses senses this and transmits the information to the wireless antenna. According to the research team, their newly-developed smart lenses with built-in pressure-sensing and glucose-monitoring sensors could still detect blood glucose and IOP despite the deformation of the contact lenses. The sensor characteristics were also maintained even when exposed to various substances in human tears. "It was observed that the live rabbit did not show any abnormal behavior when wearing the contact lens sensor," says Joohee Kim (Combined M.S./Ph.D. student of Materials Science and Engineering), the first author of the study. The contact lens sensor characteristics are not changed when the lens is deformed. Even when the sensor exposed to various materials in human tears the characteristics were maintained, and flexibility and stretchability were also excellent. Furthermore, since the electronic sensor is inserted into the soft contact lens, the feeling of wearing it is also excellent. "This study can be used to diagnose diseases (diabetes and glaucoma) by implementing two types of transparent electronic sensors in the production of smart contact lens sensors," said Professor Park. "We are now a step closer to the implementation of a fictional idea for a smart contact lens in the films, like "Minority Report" and "Mission: Impossible". More information: Joohee Kim et al, Wearable smart sensor systems integrated on soft contact lenses for wireless ocular diagnostics, Nature Communications (2017). DOI: 10.1038/ncomms14997


News Article | May 4, 2017
Site: www.eurekalert.org

A recent study, affiliated with UNIST has proposed the possibility of in situ human health monitoring simply by wearing a contact lens with built-in wireless smart sensors. This study has been jointly conducted by Professor Jang-Ung Park of Materials Science and Engineering, Professor Chang Young Lee of Life Science, and Professor Franklin Bien of Electrical and Computer Engineering at UNIST in collaboration with Professor Hong Kyun Kim of Ophthalmology and Professor Kwi-Hyun Bae of Internal Medicine at Kyungpook National University (KNU). In the study, the research team unveiled a smart contact lens sensor that could help monitor biomarkers for intraocular pressure (IOP), diabetes mellitus, and other health conditions. The research team expects that this research breakthrough could lead to the development of biosensors capable of detecting and treating various human diseases, and used as a component of next-generation smart contact lens-related electronic devices. Diabetes is the most common cause of high blood sugar levels. Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma. If this condition persists for more than two hours, a patient will be diagnosed with diabetes. Since blood sugar can be measured with tears, many attempts have been made to monitor diabetes with contact lenses. Despite numerous studies in the last several decades, the biggest drawback with conventional smart contact lenses was thought to be poor wearability. The electrodes used in existing smart contact lenses are opaque, and therefore obscure the view when wearing it. Moreover, because they lens-shaped firm plastic material, many people complain of comfort issues with contact lens wear which made wearing them impossible. Professor Park and his research team solved these issues by developing a sensor based on transparent and flexible materials. Their new smart contact lens sensors use electrodes made of highly stretchable and transparent graphene sheets and metal nanowires. Using this sensor, patients with diabetes and glaucoma may one day be able to self-monitor blood glucose levels and eye pressure. Through the embedded wireless antenna in the contact lens sensor, patients can also transmit their health information, which allows real-time monitoring of their health conditions, as well. In addition, because the system uses wireless antenna to read sensor information, no separate power source, like battery is required for the smart contact lens sensors. Intraocular pressure measurement can be achieved using the dielectric layers. The dielectric layer is an electrically non-conductive layer, characterized by polarity that divides both positive and negative charges. The thickness of this layer changes from thinning as the intraocular pressure increases, to thickening as the intraocular pressure decreases. The IOP sensor, embedded in the contact lenses senses this and transmits the information to the wireless antenna. According to the research team, their newly-developed smart lenses with built-in pressure-sensing and glucose-monitoring sensors could still detect blood glucose and IOP despite the deformation of the contact lenses. The sensor characteristics were also maintained even when exposed to various substances in human tears. "It was observed that the live rabbit did not show any abnormal behavior when wearing the contact lens sensor," says Joohee Kim (Combined M.S./Ph.D. student of Materials Science and Engineering), the first author of the study. The contact lens sensor characteristics are not changed when the lens is deformed. Even when the sensor exposed to various materials in human tears the characteristics were maintained, and flexibility and stretchability were also excellent. Furthermore, since the electronic sensor is inserted into the soft contact lens, the feeling of wearing it is also excellent. "This study can be used to diagnose diseases (diabetes and glaucoma) by implementing two types of transparent electronic sensors in the production of smart contact lens sensors," said Professor Park. "We are now a step closer to the implementation of a fictional idea for a smart contact lens in the films, like "Minority Report" and "Mission: Impossible". The results of the study have been published in the March issue of the renowned scientific journal, Nature Communications. It was carried out with the support of the 2017 CooperVision Science and Technology (S&T) Awards Program. Joohee Kim, et al. "Wearable Smart Sensor Systems Integrated On Soft Contact Lenses For Wireless Ocular Diagnostics", Nature Communications, (2017).


Sprout Health Group Hires Former Fire Captain for Their Vice President of Business Development Sprout Health Group (www.sprouthealthgroup.com), a healthcare managment company that provides PHP/IOP treatment for adults suffering from the disease of addiction and co-occurring mental health issues, hires Mark Lamplugh. Eatontown, NJ, April 21, 2017 --( In his role, Lamplugh will add his expertise in not only program development and expansion but as a renowned expert and author on first responder treatment and recovery. Lamplugh is a fourth-generation firefighter and former captain with the Lower Chichester (PA) Fire Company. Lamplugh was the Chief Executive Officer of 360 Wellness Inc (www.360wellness.org). and is nationally recognized in Crisis Stress Intervention through the American Academy of Experts in Traumatic Stress. Lamplugh has been instrumental in creating new programs for first responders across the country as they deal with the stress and depression that often comes with their occupations and intends on continuing this work at Sprout Health Group. Lamplugh played a key role in developing Frontline Responder Services (www.frontlinerehab.com) which has been one of the fastest growing responder programs in the country and a key focus for Sprout Health Group (www.sproutheathgroup.com) over the last year. Sprout Health Group (www.sprouthealthgroup.com) managing partner Asher Meister-Aldama is looking forward to the future of the Sprout Health Group treatment programming with the addition of Lamplugh. "Mark brings a unique and much-needed perspective to our team," stated Meister-Aldama. "Responder treatment has yet to become what it needs to become to heal the wounds these heroes suffer daily." "Finding better ways to bring addiction and mental health programs to first responders suffering has been a long-term goal of mine," said Lamplugh. "There is an increased number of PTSD and Suicides in the first responder community. PTSD raises a responder's suicide risk, but even less-severe injuries can contribute to problems like personal anxiety and poor health, family problems, abuse of alcohol and drugs, withdrawal, depression and burnout." Lamplugh attributes the growing problems nationwide to the unrest the United States has experienced over the last decade. "We have law enforcement succumbing to hyper-vigilance, over-worked trauma teams, and firefighters that are handling everything from fires to terrorist attacks. Add in the natural disasters we have experienced, and you can see why the numbers are rising," Lamplugh explained. "Having programs like this at Sprout Health Group is just one more step toward meeting those increased challenges." "Sprout Health Group (www.sprouthealthgroup.com) believes that addiction and mental health issues should be treated simultaneously," said Meister-Aldama. "Mark brings more of that balance to us with his vast history of working with other treatment programs and his present involvements as an author, consultant and advisor to public safety agencies nationwide." About Sprout Health Group The Sprout Health Group is a healthcare management company that owns and operates drug and alcohol rehab centers and medical detox facilities across the United States. Eatontown, NJ, April 21, 2017 --( PR.com )-- Sprout Health Group (www.sprouthealthgroup.com), a healthcare management company that provides PHP/IOP treatment for adults suffering from the disease of addiction and co-occurring mental health issues, announced today that Mark Lamplugh had been brought on as their new Vice President of Business DevelopmentIn his role, Lamplugh will add his expertise in not only program development and expansion but as a renowned expert and author on first responder treatment and recovery. Lamplugh is a fourth-generation firefighter and former captain with the Lower Chichester (PA) Fire Company. Lamplugh was the Chief Executive Officer of 360 Wellness Inc (www.360wellness.org). and is nationally recognized in Crisis Stress Intervention through the American Academy of Experts in Traumatic Stress.Lamplugh has been instrumental in creating new programs for first responders across the country as they deal with the stress and depression that often comes with their occupations and intends on continuing this work at Sprout Health Group. Lamplugh played a key role in developing Frontline Responder Services (www.frontlinerehab.com) which has been one of the fastest growing responder programs in the country and a key focus for Sprout Health Group (www.sproutheathgroup.com) over the last year.Sprout Health Group (www.sprouthealthgroup.com) managing partner Asher Meister-Aldama is looking forward to the future of the Sprout Health Group treatment programming with the addition of Lamplugh. "Mark brings a unique and much-needed perspective to our team," stated Meister-Aldama. "Responder treatment has yet to become what it needs to become to heal the wounds these heroes suffer daily.""Finding better ways to bring addiction and mental health programs to first responders suffering has been a long-term goal of mine," said Lamplugh. "There is an increased number of PTSD and Suicides in the first responder community. PTSD raises a responder's suicide risk, but even less-severe injuries can contribute to problems like personal anxiety and poor health, family problems, abuse of alcohol and drugs, withdrawal, depression and burnout."Lamplugh attributes the growing problems nationwide to the unrest the United States has experienced over the last decade. "We have law enforcement succumbing to hyper-vigilance, over-worked trauma teams, and firefighters that are handling everything from fires to terrorist attacks. Add in the natural disasters we have experienced, and you can see why the numbers are rising," Lamplugh explained. "Having programs like this at Sprout Health Group is just one more step toward meeting those increased challenges.""Sprout Health Group (www.sprouthealthgroup.com) believes that addiction and mental health issues should be treated simultaneously," said Meister-Aldama. "Mark brings more of that balance to us with his vast history of working with other treatment programs and his present involvements as an author, consultant and advisor to public safety agencies nationwide."About Sprout Health GroupThe Sprout Health Group is a healthcare management company that owns and operates drug and alcohol rehab centers and medical detox facilities across the United States. Click here to view the list of recent Press Releases from Sprout Health Group


Hexaware Technologies Limited that Everest Group has ranked it among the top 20 IT services (ITS) providers, as part of its PEAK Matrix Service Provider. --, a leading global provider of Application, Infrastructure, BPS and Digital services announced that Everest Group has ranked it among the top 20 IT services (ITS) providers, as part of its PEAK Matrix Service Provider of the Year™ awards for 2017.evaluations were designed to serve as a valuable source for IT services' buyers to evaluate, compare and contrast key service providers in the global services market space. These assessments offer service provider selection guidance, as well as nuanced insights into those providers' strategies for key business lines, geographies, and technologies. The awards recognize consistent top performers across 21 PEAK Matrix IT services evaluations, featuring 73 providers that were published in 2016."This PEAK Matrix Service Provider of the Year award is a significant achievement for us. Hexaware is helping organizations reimagine their businesses, shrink IT costs, enhance business operations, accelerate digital transformation and maximize returns leveraging its Shrink IT Grow Digital strategy," said. "In an industry that is thriving on labor arbitrage for too long, Hexaware is at the forefront of eliminating labor through automation, Artificial Intelligence, Machine language and by every other means available," said Krishna Kumar, Chief Technology Officer, Hexaware Technologies Ltd.As a Gen 3.0 IT service organization, Hexaware has introduced new services to its clients like RAISE IT, platform driven infrastructure and application management services, RPA enabled Digital Managed Services etc., which are in-line with the company's corporate strategy. RAISE IT leverages cutting-edge Artificial Intelligence, Cognitive Analytical Engine, a Big data platform for IT Operations coupled with Robotic Incident Management and disrupts the current state of IT Services delivery. Hexaware's Digital Managed Services (DMS) spans the entire managed services process, assumes the risk of implementing Robotic Process Automation, and provides strategic cost and risk benefits from day one. All these investments around innovative service offerings enabled Hexaware to grow as the fastest growing IOP in 2016 with 9.0% YoY growth in constant currency terms.About Hexaware,. The Company focuses on key domains such as Banking, Financial Services, Capital Market, Healthcare, Insurance, Manufacturing, Retail, Education, Telecom, Travel, Transportation, and Logistics. Hexaware is committed to delivering business results and leverage technology solutions by specializing in Application Development & Maintenance, Business Intelligence & Analytics, Quality Assurance and Testing Services, Infrastructure Management Services, Business Process Services and Enterprise Solutions. Founded in 1990, Hexaware has a well-established global delivery model armed with proprietary tools and methodologies, skilled human capital and SEI CMMI-Level 5 certification.Safe Harbor Statement Certain statements in this press release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Hexaware has made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry.For more information log on to www.hexaware.com


The Los Angeles region's most dedicated treatment professionals are researching the use of social media as a treatment support method Insight Treatment Programs, the L.A. area's first Intensive Outpatient Program (IOP), is partnering with UCLA in a study for Parents of Teens in Substance Abuse Treatment. The study, titled "Purpose," will examine the use of private Facebook groups as a support method for families with teenagers struggling with mental health and drug and alcohol issues. UCLA's Integrated Substance Abuse Programs (ISAP) received a 2-year grant to study how groups on Facebook and other social media platforms can be used toward effectively supporting parents of teens and young adults suffering from addiction. The National Institute on Drug Abuse (NIDA) is funding the program. Anthony Lopez, Founder of Insight Treatment Programs in Pasadena and Sherman Oaks, said he is introducing the study to parents in the program for them to act as peer leaders in the Facebook groups. 'Insight Treatment Programs' is a recognized intensive outpatient treatment program for teens and early young adults (14-20 years of age) suffering from mental health and addiction issues. "It is important that we support such initiatives and learn how to utilize existing social media platforms to ensure better support to parents who don't have access to intensive treatment programs like Insight Treatment Programs," said Lopez. "The idea is to document how important parent support can be on social media and get additional funding to promote this type of support nationwide." The study runs 8 weeks and participants must have a 13-to-18-year-old child in treatment for substance abuse. The testing involves membership in a private Facebook group as a way to communicate and relate with other like-minded parents and guardians to share experiences and compare viable solutions. Clinical psychologist Dr. Mayra Schulte is the Principle Investigator of the program. According to her website, "The goal of PURPOSE is to enhance parental support of and involvement in their child’s recovery through the use of online peer-led groups that provide information, emotional support, and skills." UCLA's ISAP, part of The Semel Institute for Neuroscience & Human Behavior, is a publicly available resource for substance abuse treatment among students, fellows and clinicians. The research it conducts supports and informs key decision makers in public policy, health services, criminal justice, epidemiology, and those in the behavioral science field. For more information, or to make an inquiry about participating in Purpose, call 310-267-5289.

Loading IOP collaborators
Loading IOP collaborators